As single agent, in a phase 1 study enrolling 268 R/R IDH1-mutated AML patients ineligible for standard therapy, ivosidenib induced an overall response rate (ORR) of 41.6%, with a duration of CR of 9.3 months [96]. The gene discussed is IDH1; the disease is acute myeloid leukemia.